Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control

被引：1
|
作者：
Blauvelt, Andrew [1 ]
Langley, Richard G. [2 ]
Peris, Ketty [3 ]
Silvestre, Juan Francisco [4 ]
Katoh, Norito [5 ]
Tauber, Marie [6 ,7 ]
Pinter, Andreas [8 ]
Ameen, Mahreen [9 ]
Gooderham, Melinda [10 ,11 ]
Oland, Christian Bjerregard [12 ]
Tindberg, Ann-Marie [12 ]
Gjerum, Le [12 ]
Reich, Kristian [13 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[3] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy
[4] Hosp Gen Univ Dr Balmis, Dermatol Dept, ISABIAL, Alicante, Spain
[5] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan
[6] Lyon Sud Hosp, Dept Allergol & Clin Immunol, Lyon, France
[7] INSERM, CIRI, U1111, Lyon, France
[8] Goethe Univ Frankfurt Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[9] Royal Free London Natl Hlth Serv Fdn Trust, London, England
[10] SKiN Ctr Dermatol, Peterborough, ON, Canada
[11] Queens Univ, Dept Dermatol, Kingston, ON, Canada
[12] LEO Pharma AS, Ballerup, Denmark
[13] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
long-term; efficacy; ECZTEND; tralokinumab; moderate-to-severe;
D O I：
10.1093/bjd/ljad498.050
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
551
引用
收藏
页码：II48 / II49
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [42] Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
    Andreas Kuznik
    Gaëlle Bégo-Le-Bagousse
    Laurent Eckert
    Abhijit Gadkari
    Eric Simpson
    Christopher N. Graham
    LaStella Miles
    Vera Mastey
    Puneet Mahajan
    Sean D. Sullivan
    Dermatology and Therapy, 2017, 7 : 493 - 505
  • [43] Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
    Khattri, S.
    Brunner, P. M.
    Garcet, S.
    Finney, R.
    Cohen, S. R.
    Oliva, M.
    Dutt, R.
    Fuentes-Duculan, J.
    Zheng, X.
    Li, X.
    Bonifacio, K. M.
    Kunjravia, N.
    Coats, I.
    Cueto, I.
    Gilleaudeau, P.
    Sullivan-Whalen, M.
    Suarez-Farinas, M.
    Krueger, J. G.
    Guttman-Yassky, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S41 - S41
  • [44] Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan, I
    Rubini, Norma P. M.
    Pires, Mario C.
    Rossi, Ana B.
    Zhang, Annie
    Chen, Zhen
    Levit, Noah A.
    Chao, Jingdong
    Shumel, Brad
    Bego-Le Bagousse, Gaelle
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (05): : 1279 - +
  • [45] Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
    Kuznik, Andreas
    Bego-Le-Bagousse, Gaelle
    Eckert, Laurent
    Gadkari, Abhijit
    Simpson, Eric
    Graham, Christopher N.
    Miles, LaStella
    Mastey, Vera
    Mahajan, Puneet
    Sullivan, Sean D.
    DERMATOLOGY AND THERAPY, 2017, 7 (04) : 493 - 505
  • [46] Efficacy and safety of 611 for the treatment of moderate-to-severe atopic dermatitis in adults
    Zhang, Jianzhong
    Zhao, Yan
    Zhou, Qinghong
    Xu, Yuyu
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I54 - I55
  • [47] Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
    Blauvelt, Andrew
    Langley, Richard G.
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew E.
    Peris, Ketty
    Fangel, Stine
    Gjerum, Le
    Corriveau, Joshua
    Saeki, Hidehisa
    Warren, Richard B.
    Simpson, Eric
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 815 - 824
  • [48] Long-Term Safety, Efficacy, and Adherence of Tralokinumab for the Treatment of Patients with moderate to severe atopic Dermatitis over a Period of up to 3 Years: Interim Analysis of ECZTEND, a Phase III Long-Term Extension Study
    Wollenberg, Andreas
    Blauvelt, Andrew
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Herranz, Pedro
    Pink, Andrew
    Peris, Ketty
    Saeki, Hidehisa
    Beissert, Stefan
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 19 - 20
  • [49] Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1
    Eric L. Simpson
    Andrew Blauvelt
    Jonathan I. Silverberg
    Michael J. Cork
    Norito Katoh
    Thomas Mark
    Shannon K. R. Schneider
    Andreas Wollenberg
    American Journal of Clinical Dermatology, 2024, 25 : 139 - 148
  • [50] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12345